28 April 2020 - NICE has now issued a positive Final Appraisal Document recommending Janssen's Stelara (ustekinumab) as an option for treating ulcerative colitis, having initially rejected the drug earlier this year.

Specifically, NHS funding is being approved for use to treat moderately to severely active ulcerative colitis in adults when conventional therapy or a biological agent cannot be tolerated, or the disease has responded inadequately or lost response to treatment, only if: a tumour necrosis factor-alpha inhibitor has failed, cannot be tolerated, or is unsuitable.

Read Pharma Times article